Sternberg, C. N., Daugaard, G., Geczi, L., Hotte, S. J., Mainwaring, P. N., Saad, F., … George, D. J. (2014). Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy. In Journal of Clinical Oncology (Vol. 32, pp. 5061–5061). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5061

Sternberg, Cora N., Gedske Daugaard, Lajos Geczi, Sebastien J. Hotte, Paul N. Mainwaring, Fred Saad, Ciro Souza, et al. “Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.” In Journal of Clinical Oncology, 32:5061–5061. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5061.

Sternberg CN, Daugaard G, Geczi L, Hotte SJ, Mainwaring PN, Saad F, et al. Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5061–5061.

Sternberg, Cora N., et al. “Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5061–5061. Crossref, doi:10.1200/jco.2014.32.15_suppl.5061.

Sternberg CN, Daugaard G, Geczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JMT, Galli L, Londhe A, De Porre P, Atlan D, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ. Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5061–5061.